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Background External validity of study results is an important issue from a clin-
ical point of view. From a methodological point of view, however,
the concept of external validity is more complex than it seems to be
at first glance.
Methods Methodological review to address the concept of external validity.
Results External validity refers to the question whether results are general-
izable to persons other than the population in the original study.
The only formal way to establish the external validity would be to
repeat the study for that specific target population. We propose a
three-way approach for assessing the external validity for specified
target populations. (i) The study population might not be represen-
tative for the eligibility criteria that were intended. It should be
addressed whether the study population differs from the intended
source population with respect to characteristics that influence
outcome. (ii) The target population will, by definition, differ from
the study population with respect to geographical, temporal and
ethnical conditions. Pondering external validity means asking
the question whether these differences may influence study results.
(iii) It should be assessed whether the study’s conclusions can be
generalized to target populations that do not meet all the eligibility
criteria.
Conclusion Judging the external validity of study results cannot be done by
applying given eligibility criteria to a single target population.
Rather, it is a complex reflection in which prior knowledge, statis-
tical considerations, biological plausibility and eligibility criteria
all have place.
Keywords Clinical trial, external validity
Introduction
In clinical trials the effect of therapeutic interventions
is estimated in persons who enrolled in a trial: the
study population. Internal validity refers to the question
whether the study results are valid for the original
study population. External validity concerns the gen-
eralizability of study results to persons other than the
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original study population.1 We call the population of
patients to whom the results should be generalizable
the target population.
Internal validity is a prerequisite for the external valid-
ity. Study results that deviate from the true effect due to
systematic error lack the basis for generalizability. Next,
however, from a clinician’s point of view the general-
izability of study results is of paramount importance.
According to the CONSORT statement external validity
should be addressed in reporting randomized clinical
trials (RCTs).1 It is surprising how often external valid-
ity is neglected in methodological considerations about
research.2,3 Two reasons might account for this neglect:
first, most clinical trails are directed towards the assess-
ment of treatment effects in an ideal setting, and not
towards the question whether the intervention has a
positive effect when applied in routine clinical practice;
and secondly, the concept of external validity is more
complex than it seems to be from the deceptively simple
description that it concerns generalizability of results to
persons who were not included in the original study.
Clinical trials: internal validity,
external validity and applicability
Trial results are obtained in persons who are included
in the study as a representative fraction of an under-
lying source population. The internal validity of study
results refers to the question whether the results
suffer from systematic error. A study can be judged
to be internally valid when the effect estimate differs
from the true effect that would be obtained in the
total source population only because of random error.
The terms generalizability, external validity, applic-
ability, transferability and extrapolation are all used
with overlapping meanings. We will not dwell on
potential differences in meaning, but we will make
a distinction between ‘external validity’and ‘applic-
ability’. External validity will be used to denote the
question whether the study results are valid for
patients other than those in the original study popu-
lation in a treatment setting that is in all respects
equal to the treatment setting of the original study.
External validity therefore involves patient and disease
characteristics. Study results can be generalized to a
specific target population if, and only if, the results
are externally valid for this specific target population.
In contrast, we refer to applicability as the question
whether study results are valid for patients to whom
results are generalizable but who are in a different
treatment setting than the original study population.
Consequently, applicability involves characteristics of
the treatment setting. For instance, if a neurosurgical
intervention works well within a hospital with an
experienced neurosurgeon, the results might in prin-
ciple be generalizable to a similar population of
patients. However, if a specific hospital lacks experi-
enced neurosurgeons the applicability of the study
findings might be limited. The proposed distinction
between external validity and applicability may not
always be clear-cut. For example, treatment effects
of antibiotics depend on patient characteristics as
well as resistance patterns within a specific treatment
setting. However, the fact that this conceptual distinc-
tion is not clear-cut in all respects is no compelling
argument against its use. Similarly, the distinction
between selection bias and confounding by indication
is widely used, although the boundaries are not clear-
cut for all situations.
In addition, the value of clinical outcome of the
treatment for an individual patient needs to be
assessed. Moreover, individual circumstances could
be taken into account to assess whether an individual
patient should be treated according to the results of a
trial or not.4 For the purpose of this article, we will
not go into the details of clinical relevance and indi-
vidual treatment decisions.
Can external validity be
formalized?
How can external validity be conceptualized to facil-
itate its assessment? One way that seems at first sight
appealing is to define it in analogy to internal validity.
A study is assessed to be internally valid when the
study results differed from the true effect only
because of random error. Analogously, a study
would be externally valid if the study results differed
from the value that would be obtained in the target
population only because of random error. Thus, the
assessment whether study results are externally valid
would mean judging whether the results are valid for
a defined target population. However, this approach is
problematic.
Because external validity depends on a target popu-
lation, the first step in the assessment of the external
validity is to define this target population. The pro-
blem is that in clinical practice different doctors may
want to apply the same research evidence to different
target populations. For instance, suppose a study
exists on the effect of antihypertensive drugs in
patients between ages 45 and 74 years, with diastolic
dysfunction but without severe co-morbidity. There
are several possibilities to define target populations
for this specific study. One doctor might strictly
want to generalize to persons in the age bracket 45–
74 years. However, another may wish to apply the
results to all adult hypertensive patients with diastolic
dysfunction without severe co-morbidity; referring to
hypertensive patients <45 years as well as474 years.
Indeed, if patients 474 years were excluded from a
study, should its external validity be restricted
to patients below this age limit? Is there any reason
to believe that the effects of the therapeutic interven-
tion are not generalizable to 76-year-old patients?
Or to those who are 77 years old? Likewise, would
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the results not be generalizable to a 40-year old? But
where should this extension of generalizability stop?
Next, the severity of co-morbidity might be perceived
in different ways. Should uncomplicated diabetes
mellitus, treated with oral medication, considered to
be a severe co-morbidity? And what about diabetes
treated with insulin? It becomes clear that there is
no single commonly agreed predefined target popula-
tion for a given study. The question on generalizabil-
ity must be pondered for various target populations,
i.e. different types of patients, and the external valid-
ity should be assessed for each.
Of course, a counterargument might be that the
target population is strictly defined by the eligibility
criteria of the original study, which seems to solve the
problem of the multiplicity of the external validity for
one single study. Even if we leave aside that these
criteria are often incompletely described in original
reports,5 this definition of the target population does
not allow for a satisfactory conceptualization of exter-
nal validity either. A target population that perfectly
fits the eligibility criteria will, by definition, still differ
from the original study population with respect to
geographical, ethnical and temporal conditions.
Each of these differences might affect the outcome
of interest. For instance, in a study on the effect of
clopidrogel in patients with acute myocardial infarc-
tion, 45 852 Chinese patients were included.6 A target
population could be defined strictly according to the
inclusion criteria, i.e. patients within 24 h after onset
of acute myocardial infarction. However, the question
whether the results are generalizable to patients with
the same condition from other countries or ethnic
groups would remain unanswered. This may be
relevant, since, for instance, for another drug, the
ACE-inhibitor trandolapril, it has been shown that
its effect on blood pressure is modified by ethnicity.7
These considerations show that, in a very strict sense,
the external validity of study results cannot be taken
for granted even when the target population is
defined by the same eligibility criteria of the original
study.
In addition, external validity can also be affected
because the original study population was not truly
representative for the intended eligibility criteria. In a
comparison between eligible patients with myocardial
infarction who were and were not included in an
RCT, important differences were found.8 The included
patients were younger, had less co-morbidity and
their mortality was lower compared with the excluded
patients. In other studies, patients who gave consent
to participate in research differed from non-consen-
ters in characteristics that can determine outcome.9,10
This highlights that study populations can differ in a
meaningful way from all patients who would fulfil
the eligibility criteria.
These considerations show that external validity
cannot be readily formalized. Although the eligibility
criteria of the original report might be used in an
attempt to define a target population, this does not
guarantee the generalizability of the results to this
specific target population that consists of new
patients treated in other countries in diverse settings.
The only formal way to establish the external validity
would be to repeat the study in the specific target
population, which would be rather unpractical given
the large number of RCTs and an even larger number
of potential target populations. Nonetheless, despite
the lack of a clear definition and the lack of a
formal way of proving that external validity for a spe-
cified target population exists, we have to judge exter-
nal validity as being able to use the results of a
particular randomized trial.
How can external validity be
assessed?
The assessment of the external validity of clinical
trials is a complex reflection in which eligibility cri-
teria, prior knowledge, statistical considerations and
biological plausibility are all involved. We propose a
three-step approach to assess the external validity of
therapeutic research. In addition, the applicability of
study results should be addressed. These four aspects
of generalizability are summarized in Table 1 and dis-
cussed in more detail below.
External validity and eligibility criteria
Eligibility criteria provide an approximate guide for
generalizability. Indeed, the study population might
not be representative for a population defined by its
eligibility criteria, which can be the case when only a
fraction of all eligible patients is actually included.9,10
The proportion of patients actually included may
serve as a good indicator for unaccounted selectivity
in enrolment. Other aspects of a study, like the use of
a run-in period, can limit the generalizability. During
a run-in period, patients who do not comply or have
side effects on study medication are excluded.11 In an
RCT on the effect of carvedilol in patients with
chronic heart failure, during the run-in period, 6%
of the patients were excluded due to progressive
heart failure or death.12 The exclusion of these
patients may have led to an underestimation of the
rate of adverse events and an overestimation of ben-
eficial effects.11 When patients are included in tertiary
care referral centres, disease characteristics may differ
from patients treated in non-referral centres or in
general practice, which is not accounted for by the
eligibility criteria. The first element in the assessment
of external validity should address the question
whether the study population differs from the
source population with respect to characteristics that
influence outcome. If so, the eligibility criteria are not
a proper reflection of the study population and this
might limit the study’s external validity.
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Temporal, ethnical and geographical aspects
Any target population will, by definition, differ from
the study population with respect to temporal, ethni-
cal, socio-economic and geographical conditions.
Pondering external validity means asking whether
these differences may influence the results and limit
generalizability. For example, in studies on antibiotics,
temporal and geographical differences can translate
into differences in resistance patterns with impact
on the effect of antibiotic treatment. Studies per-
formed in the past or in another country might
therefore not be generalizable to the intended patient
populations. In addition, ethnic differences between
study population and target population may influence
generalizability. However, it is difficult to make a
prior estimation on the possible interaction
between ethnicity and treatment effects. Whereas
the response to antihypertensives clearly depends on
ethnicity,13 the beneficial effects of aspirin in patients
with acute ischaemic stroke were similar in a
European and a Chinese population.14,15 Geographic
differences can translate into different treatment
effects. For instance, the effect of vitamin D may
depend on latitude16 but also on ethnicity and seaso-
nal effects.17
External validity beyond eligibility criteria
It is necessary to assess whether the conclusions of a
study can be generalized to target populations that do
not meet all the eligibility criteria. If studies were
only generalizable to target populations that fulfil a
study’s eligibility criteria, this would encompass only
a very small proportion of patients in daily practice.
For instance, when the potential eligibility of asthma
patients seen in routine clinical practice was exam-
ined, only 4–6% of them would have met the eligibil-
ity criteria of RCTs in asthma.18 A similarly low
percentage was found in a comparable study in
chronic obstructive pulmonary disease (COPD)
patients.19
About 50 years ago, Doll and Hill assessed the
relationship between smoking and lung cancer
in 59 600 doctors.20 There is little doubt that these
results are generalizable to athletes and statisticians,
although no specific studies were done in these
populations. The reason for the generalizability
Table 1 Strategy to assess the external validity and applicability of clinical trialsa
(i) External validity and eligibility criteria
Are the eligibility criteria a proper reflection of the study population? If this is not the case, the external validity might be limited
 Selection of study population Patients who give consent to participate differ from non-consenters in
characteristics that can determine outcome. The proportion of eligible patients
that is actually included gives useful information about a potential degree
of selectivity.
 Run-in period The use of a run-in period may exclude non-compliant participants or
participants at higher risk for side effects.
 Participating centres Patients in secondary or tertiary referral centres differ from patients in
non-referral centres and general practices.
(ii) Temporal, ethnical, socio-economic and geographical aspects
Do temporal, ethnical and geographical differences between study population and target populations translate in to a limited
generalizability?
 Temporal aspects The time elapsed since the original study was performed may translate into
important changes in medical practice that influence treatment effects.
 Ethnical aspects Ethnicity may interact with treatment effect.
 Geographical and socio-economic
aspects
Geographical and socio-economic differences between study population
and target population may affect treatment effects.
(iii) External validity beyond eligibility criteria
Can study results be generalized beyond the eligibility criteria?
 Age RCTs mostly use strict age criteria. Generalizability beyond age criteria should
be based on prior knowledge and biological plausibility.
 Co-morbidities RCTs often exclude patients with co-morbidity. Generalizability to patients
with co-morbidities should only be done with caution, and can only be
based on external evidence.
(iv) Applicability of study results
Do differences in treatment setting translate into possible differences in treatment effects?
 Treating physicians Treatment effects can depend on skills of treating physicians.
 Treatment setting The setting of the treatment, i.e. the use of a study nurse, the frequency of
controls and the availability of diagnostic procedures, may influence treatment
results.
 Administrative policy Administrative policies will influence treatment effects, especially for acute
diseases that require treatment within a defined time window.
aThis table includes relevant aspects that should be considered when assessing the external validity and applicability of clinical
trials but is not exhaustive.
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is 2-fold. First, the relationship between lung cancer
and smoking was established in additional studies, in
very diverse situations—even if not for all potential
combinations: for instance there are no specific stu-
dies in white female athletes. Secondly, there is no
reason to doubt that the effect of smoking is different
in the lungs of doctors compared with others, such as
athletes. For reasons that are grounded in prior
knowledge and biological plausibility the external
validity could be extended to populations that were
not eligible in the original study, nor ever studies
specifically. In the same way, study results are
often generalized beyond their specific age bands
(see above).
Applicability of study results
Generalizability does not necessarily mean that study
results are applicable.21 As noted above ‘applicability’
concerns treatment settings. For example, a positive
effect of spironolacton in patients with heart failure
was shown in an RCT.22 However, in observational
studies the rate of severe hyperkalemia was reported
to be much higher than in the original RCT.23 In the
RCT, patients were probably seen more frequently,
thereby enhancing the probability of detecting the
hyperkalemia at an early stage. This example shows
that, although the results might have been perfectly
generalizable, their applicability was limited because
routine treatment settings differ from the setting in
the original study. Also, other aspects of health care
settings, such as administrative policies and diagnostic
facilities, may influence treatment results in a way that
is not determined by disease or patient characteristics.
Conclusion
Unlike internal validity, external validity cannot be
easily formalized. The term external validity was
called a misnomer,24 because it suggests objectivity
and a clear definition that it cannot satisfy. It is
therefore not surprising that there is currently no con-
sensus about how to assess the external validity of
study results. Judgment of external validity of study
results cannot be done by applying eligibility criteria
to arrive at one single target population. Rather, it is a
complex reflection in which prior knowledge, statisti-
cal considerations, biological plausibility and eligibil-
ity criteria all have place. The assessment of external
validity is, at best, a well-argued, but fallible, state-
ment about generalizability.
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It is now widely accepted that in most situations,
randomized controlled trials (RCTs) and systematic
reviews are the most reliable methods of determining
the effects of treatment. Yet, the methodology is still
relatively new (a few decades old), and so our under-
standing of trial design, and more especially of
how best to make use of results, is less than perfect.
RCTs must be internally valid (i.e. their design and
conduct must minimize the possibility of bias),
and, until recently, guidelines on trial methodology
and reporting, such as the CONSORT initiative, con-
centrated almost completely on issues related to inter-
nal validity. However, to be clinically useful, the result
of a trial must also be relevant to clinical practice, i.e.
be reasonably likely to be replicated when applied to
a definable group of patients in a particular clinical
setting. The extent to which a result can be extrapo-
lated in this way has been variously termed as ‘exter-
nal validity, applicability or generalizability’.1
For some interventions, such as lowering blood
pressure in chronic uncontrolled hypertension, the
benefits have been shown to be generalizable to
the vast majority of patients and settings, but the
effects of other interventions will often depend on
factors such as the characteristics of the patient, the
method of application of the intervention and the set-
ting of treatment. How these factors are taken into
account in the design and performance of an RCT and
in the reporting of the results can have a major
impact on the clinical usefulness of the result. Lack
of external validity has always been the most frequent
criticism by clinicians of RCTs, systematic reviews and
guidelines. Although much more research is required,
systematic assessments of the external validity of
trials in specific areas of medicine are now beginning
to demonstrate the often substantial disparity
between the information that is provided by RCTs
and the information that is actually required by
clinicians.2,3 This disparity is one explanation for the
underuse in routine practice of many treatments that
have been shown to be beneficial in trials and are
recommended in guidelines.
However, external validity is a ‘slippery’ concept.
It can be defined in broad terms, as above, but is
much more difficult to quantify exactly. While the
determinants of internal validity are intuitive and
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